Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose enzalutamide for CNS side effects in frail castration-resistant prostate cancer
NL-OMON52805Phase 4Active, not recruiting
- Sponsor
- Ziekenhuisapotheek
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Ziekenhuisapotheek. Primary endpoint: Change in FACIT-Fatigue score at 6 weeks. Started Jun 2019; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON52805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52805.